299 related articles for article (PubMed ID: 17530993)
41. Emergence of HIV-1 drug-resistant variants in women following antiretroviral prophylaxis for the prevention of mother to child transmission.
Mani M; Ramalingam VV; Lionel J; Christina SA; Sachithanandham J; Peedicayil A; Kannangai R
Indian J Med Microbiol; 2015; 33(2):225-30. PubMed ID: 25865972
[TBL] [Abstract][Full Text] [Related]
42. Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission.
Flys TS; Donnell D; Mwatha A; Nakabiito C; Musoke P; Mmiro F; Jackson JB; Guay LA; Eshleman SH
J Infect Dis; 2007 Mar; 195(5):711-5. PubMed ID: 17262714
[TBL] [Abstract][Full Text] [Related]
43. Minority HIV-1 drug-resistant mutations and prevention of mother-to-child transmission: perspectives for resource-limited countries.
Samuel R; Paredes R; Parboosing R; Moodley P; Gordon M
AIDS Rev; 2014; 16(4):187-98. PubMed ID: 25300623
[TBL] [Abstract][Full Text] [Related]
44. Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.
Marcelin AG; Descamps D; Tamalet C; Cottalorda J; Izopet J; Delaugerre C; Morand-Joubert L; Trabaud MA; Bettinger D; Rogez S; Ruffault A; Henquell C; Signori-Schmuck A; Bouvier-Alias M; Vallet S; Masquelier B; Flandre P; Calvez V;
Antivir Ther; 2012; 17(1):119-23. PubMed ID: 22267476
[TBL] [Abstract][Full Text] [Related]
45. Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire.
Chaix ML; Ekouevi DK; Rouet F; Tonwe-Gold B; Viho I; Bequet L; Peytavin G; Toure H; Menan H; Leroy V; Dabis F; Rouzioux C;
J Infect Dis; 2006 Feb; 193(4):482-7. PubMed ID: 16425126
[TBL] [Abstract][Full Text] [Related]
46. [Drug resistance of HIV-1 as a result of using nevirapine for chemoprophylaxis of vertical viral transmission from HIV-infected mother to infant].
Kazennova EV
Vopr Virusol; 2009; 54(1):45-8. PubMed ID: 19253732
[TBL] [Abstract][Full Text] [Related]
47. Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine.
Martinson NA; Morris L; Gray G; Moodley D; Pillay V; Cohen S; Dhlamini P; Puren A; Bhayroo S; Steyn J; McIntyre JA
J Acquir Immune Defic Syndr; 2007 Feb; 44(2):148-53. PubMed ID: 17117145
[TBL] [Abstract][Full Text] [Related]
48. Selection of resistance mutations in children receiving prophylaxis with lamivudine or nevirapine for the prevention of postnatal transmission of HIV.
Giuliano M; Galluzzo CM; Germinario EA; Amici R; Bassani L; Dehò L; Vyankandondera J; Mmiro F; Okong P; Vella S
J Acquir Immune Defic Syndr; 2006 May; 42(1):131-3. PubMed ID: 16763503
[No Abstract] [Full Text] [Related]
49. Nonnucleoside reverse transcriptase inhibitor concentrations during treatment interruptions and the emergence of resistance: a substudy of the ISS-PART Trial.
Pirillo M; Palmisano L; Pellegrini M; Galluzzo C; Weimer L; Bucciardini R; Fragola V; Andreotti M; Marchei E; Pichini S; Vella S; Giuliano M
AIDS Res Hum Retroviruses; 2010 May; 26(5):541-5. PubMed ID: 20455761
[TBL] [Abstract][Full Text] [Related]
50. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1.
Moodley D; Moodley J; Coovadia H; Gray G; McIntyre J; Hofmyer J; Nikodem C; Hall D; Gigliotti M; Robinson P; Boshoff L; Sullivan JL;
J Infect Dis; 2003 Mar; 187(5):725-35. PubMed ID: 12599045
[TBL] [Abstract][Full Text] [Related]
51. Antiretroviral resistance patterns and HIV-1 subtype in mother-infant pairs after the administration of combination short-course zidovudine plus single-dose nevirapine for the prevention of mother-to-child transmission of HIV.
Chalermchockcharoenkit A; Culnane M; Chotpitayasunondh T; Vanprapa N; Leelawiwat W; Mock PA; Asavapiriyanont S; Teeraratkul A; McConnell MS; McNicholl JM; Tappero JW
Clin Infect Dis; 2009 Jul; 49(2):299-305. PubMed ID: 19522656
[TBL] [Abstract][Full Text] [Related]
52. A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy.
Paredes R; Puertas MC; Bannister W; Kisic M; Cozzi-Lepri A; Pou C; Bellido R; Betancor G; Bogner J; Gargalianos P; Bánhegyi D; Clotet B; Lundgren J; Menéndez-Arias L; Martinez-Picado J;
J Infect Dis; 2011 Sep; 204(5):741-52. PubMed ID: 21844300
[TBL] [Abstract][Full Text] [Related]
53. Detection of HIV drug resistance mutations in pregnant women receiving single dose Nevirapine in south India.
Jacob MS; Durairaj A; Vijayakumari J; Srijayanth P; Sivakumar MR
Indian J Pathol Microbiol; 2011; 54(2):359-61. PubMed ID: 21623090
[TBL] [Abstract][Full Text] [Related]
54. Low-frequency nevirapine resistance at multiple sites may predict treatment failure in infants on nevirapine-based treatment.
Lehman DA; Wamalwa DC; McCoy CO; Matsen FA; Langat A; Chohan BH; Benki-Nugent S; Custers-Allen R; Bushman FD; John-Stewart GC; Overbaugh J
J Acquir Immune Defic Syndr; 2012 Jul; 60(3):225-33. PubMed ID: 22395670
[TBL] [Abstract][Full Text] [Related]
55. Development of phenotypic HIV-1 drug resistance after exposure to single-dose nevirapine.
Basson AE; Ntsala M; Martinson N; Tlale E; Corrigan GE; Shao X; Gray G; McIntyre J; Puren A; Morris L
J Acquir Immune Defic Syndr; 2008 Dec; 49(5):538-43. PubMed ID: 18989222
[TBL] [Abstract][Full Text] [Related]
56. Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.
Sterrantino G; Borghi V; Callegaro AP; Bruzzone B; Saladini F; Maggiolo F; Maffongelli G; Andreoni M; De Gennaro M; Gianotti N; Bagnarelli P; Vergori A; Antinori A; Zazzi M; Zaccarelli M;
Int J Antimicrob Agents; 2019 Apr; 53(4):515-519. PubMed ID: 30769200
[TBL] [Abstract][Full Text] [Related]
57. A radiolabeled oligonucleotide ligation assay demonstrates the high frequency of nevirapine resistance mutations in HIV type 1 quasispecies of NVP-treated and untreated mother-infant pairs from Uganda.
Troyer RM; Lalonde MS; Fraundorf E; Demers KR; Kyeyune F; Mugyenyi P; Syed A; Whalen CC; Bajunirwe F; Arts EJ
AIDS Res Hum Retroviruses; 2008 Feb; 24(2):235-50. PubMed ID: 18284323
[TBL] [Abstract][Full Text] [Related]
58. Phenotypic drug resistance patterns in subtype A HIV-1 clones with nonnucleoside reverse transcriptase resistance mutations.
Eshleman SH; Jones D; Galovich J; Paxinos EE; Petropoulos CJ; Jackson JB; Parkin N
AIDS Res Hum Retroviruses; 2006 Mar; 22(3):289-93. PubMed ID: 16545016
[TBL] [Abstract][Full Text] [Related]
59. Nevirapine resistance in women and infants after first versus repeated use of single-dose nevirapine for prevention of HIV-1 vertical transmission.
Flys TS; McConnell MS; Matovu F; Church JD; Bagenda D; Khaki L; Bakaki P; Thigpen MC; Eure C; Fowler MG; Eshleman SH
J Infect Dis; 2008 Aug; 198(4):465-9. PubMed ID: 18582198
[TBL] [Abstract][Full Text] [Related]
60. Development of nevirapine resistance in infants is reduced by use of infant-only single-dose nevirapine plus zidovudine postexposure prophylaxis for the prevention of mother-to-child transmission of HIV-1.
Eshleman SH; Hoover DR; Hudelson SE; Chen S; Fiscus SA; Piwowar-Manning E; Jackson JB; Kumwenda NI; Taha TE
J Infect Dis; 2006 Feb; 193(4):479-81. PubMed ID: 16425125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
